Slipping the barrier: How variants in CARD15 could alter permeability of the intestinal wall and population health

Gut

Volumn 55, Issue 3, 2006, Pages 308-309

  Schreiber, S ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DEFENSIN; CALPROTECTIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1; MURAMYL DIPEPTIDE; NUCLEOTIDE BINDING PROTEIN; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEIN NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN 2; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

CROHN DISEASE; ENTERITIS; GENE OVEREXPRESSION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; INNATE IMMUNITY; INTESTINE EPITHELIUM CELL; INTESTINE MUCOSA PERMEABILITY; NONHUMAN; NOTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

CROHN DISEASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTESTINAL ABSORPTION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NOD2 SIGNALING ADAPTOR PROTEIN; PERMEABILITY;

EID: 33144477510     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.076075     Document Type: Note

References (37)

1. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
2. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
3. Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001;357:1925-8.
4. Lesage S, Zouali H, Cezard JP, EPWG-IBD Group, EPIMAD Group, GETAID Group, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002;70:845-57.
5. Ogura Y, Inohara N, Benito A, et al. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 2001;276:4812-18.
6. Tanabe T, Chamaillard M, Ogura Y, et al. Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition. EMBO J 2004;23:1587-97.
7. Hisamatsu T, Suzuki M, Reinecker HC, et al. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003;124:993-1000.
8. Rosenstiel P, Fantini M, Brautigam K, et al. TNF-alpha and IFN-gamma regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology 2003;124:1001-9.
9. Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005;307:731-4.
10. Maeda S, Hsu LC, Liu H, et al. Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1 beta processing. Science 2005;307:734-8.
11. Cario E, Rosenberg IM, Brandwein SL, et al. Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing Toll-like receptors. J Immunol 2000;164:966-72.
12. Abreu MT, Vora P, Faure E, et al. Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol 2001;167:1609-16.
13. Hornef MW, Frisan T, Vandewalle A, et al. Toll-like receptor 4 resides in the Golgi apparatus and colocalizes with internalized lipopolysaccharide in intestinal epithelial cells. J Exp Med 2001;195:559-70.
14. Hisamatsu T, Suzuki M, Reinecker HC, et al. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003;124:993-1000.
15. Gewirtz AT. Intestinal epithelial toll-like receptors: to protect. And serve? Curr Pharm Des 2003;9:1-5.
16. Jobin C. Intestinal epithelial cells and innate immunity in the intestine: is CARD15/Nod2 another player? Gastroenterology 2003;124:1145-9.
17. O'Neil DA, Porter EM, Elewaut D, et al. Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol 1999;163:6718-24.
18. Girardin SE, Boneca IG, Viala J, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003;278:8869-72.
19. Inohara N, Ogura Y, Fontalba A, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 2003;278:5509-12.
20. Wehkamp J, Harder J, Weichenthal M, et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal {alpha}-defensin expression. Gut 2004;53:1658-64.
21. Netea MG, Kullberg BJ, de Jong DJ, et al. NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. Eur J Immunol 2004;34:2052-9.
22. DeMeo MT, Mutlu EA, Keshavarzian A, et al. Intestinal permeation and gastrointestinal disease. J Clin Gastroenterol 2002;34:385-96.
23. Katz KD, Hollander D, Vadheim CM, et al. Intestinal permeability in patients with Crohn's disease and their healthy relatives. Gastroenterology 1989;97:927-31.
24. Teahon K, Smethurst P, Levi AJ, et al. Intestinal permeability in patients with Crohn's disease and their first degree relatives. Gut 1992;33:320-3.
25. Peeters M, Geypens B, Claus D, et al. Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology 1997;113:802-7.
26. Soderholm JD, Olaison G, Lindberg E, et al. Different intestinal permeability patterns in relatives and spouses of patients with Crohn's disease: an inherited detect in mucosal defence? Gut 1999;44:96-100.
27. Takeuchi K, Maiden L, Bjarnason I. Genetic aspects of intestinal permeability in inflammatory bowel disease. Novartis Found Symp. 2004;263:151-8, 159-63, and 211-18).
28. Thjodleifsson B, Sigthorsson G, Cariglia N, et al. Subclinical intestinal inflammation: an inherited abnormality in Crohn's disease relatives? Gastroenterology 2003;124:1728-37.
29. Wyatt J, Vogelsang H, Hubl W, et al. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993;341:1437-9.
30. Schreiber S, Nikolaus S, Hampe J, et al. Tumor necrosis factor-α and interleukin 1β in relapse of Crohn's disease. Lancet 1999;353:459-61.
31. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22.
32. Gitter AH, Bendfeldt K, Schulzke JD, et al. Leaks in the epithelial barrier caused by spontaneous and TNF-alpha-induced single-cell apoptosis. FASEB J 2000;14:1749-53.
33. Bruewer M, Luegering A, Kucharzik T, et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol 2003;171:6164-72.
34. Zeissig S, Bojarski C, Buergel N, et al. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment. Gut 2004;53:1295-302.
35. Gibson PR. Increased gut permeability in Crohn's disease: is TNF the link? Gut 2004;53:1724-5.
36. Buhner S, Buning C, Genschel J, et al. Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation? Gut 2006;55:342-7.
37. Kurzawski G, Suchy J, Kladny J, et al. The NOD2 3020insC mutation and the risk of colorectal cancer. Cancer Res 2004;64:1604-6.